Management, Abbvie Company, Richard A. Consalez, Abbot Laboratories, biopharmaceutical research and development, Abbott and ventured, medical products
The Abbvie Company was founded in the year 2013 in the United States of America. Its Chief executive officer and chairman is a 30 year old Richard A.Consalez. Its headquarters are in North Chicago, Illinois and it has 25000 employees. The journey of forming this company began on October 19, 2011, when Abbott Laboratories bore the idea of separating it into two public companies, therefore, Abbvie was founded and delved into the field of biopharmaceutical research and development, while the other, remained with the name Abbott and ventured in the field of dealing in different medical products.
[...] Its stock has surpassed the benchmark of S 500 in 2014, which is impressive for a new company. Works Cited Abbott Press Released. ``Abbott To Separate Into Two Leading Companies In Diversified Medical Products And Research Based Pharmaceuticals.''19 Oct. 2011.Web Oct Abbott Press Release. ``Abbott Selects Abbvie As The New Name for Future Research Based Pharmaceutical Company.''21 Mar.2013. Web Mar Abbbot Press Release. ``Abbott Complete Separation of Research-Based Pharmaceutical Business.''Abbott Laboratories.2 Jan 2013. Web Jan Abbvie Press Release. ``Abbvie Celebrate Launch As The New Pharmaceutical Company with Employees, patients.'' Abbvie pharmaceuticals.2 Jan.2013.Web.2 Jan. 2013. [...]
[...] The company has 21000 suppliers that are distributed all over the world. They offer the services like banking, advertisement, biological products, capital equipment and many more. Some suppliers are small and others big. All suppliers sign agreements with the company on how to keep a healthy environment and other safety measures. The company has the strategy of driving its growth organically, at the same time through acquisitions and joint ventures. On July 2014, the process of acquiring Shire, which began in June, came to a close. [...]
[...] It has also grown significantly in the stock market. In the stock market, it grew by 21.55 percent in 2014. Its rival companies like Johnson and Johnson grew by 19 percent, Pfizer by 5 percent and Novartis by 13 percent. This is an impressive show because it has been in the public for a very short time when compared with its competitors (Abbott Press Release). The projections are even higher as the year 2014 progresses. It had total revenue of 4.926 billion dollars in 2014.Its net income was 1.1 billion dollars the same year. [...]
[...] It has one business segment that is the pharmaceutical products of varied top notch brands. It relies on AndroGel, Humira, Lupron, Creon, Kaletra, Norvir and Synthroid. The brands and the others that are being developed. The company does not rely on a single drug for its revenue. Its long term programs are anchored on the innovations, acquisitions and expansions. It faces competition from other drug manufacturing companies. This has made it to be very innovative so that it is not overtaken, consequently, lowering the sales revenue. [...]
Online readingwith our online reader
Content validatedby our reading committee